The effects of ziprasidone on motor functions in experimental parkinson model in mice

International Journal of Pharmacology

Volumn 8, Issue 5, 2012, Pages 396-402

  Kilic, Fatma Sultan ^a   Kaygisiz, Bilgin ^a   Baydemir, Canan ^a   Erol, Kevser ^a  

^a ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

Author keywords

Atypical antipsychotics; Motor function; Parkinson's disease psychosis; Ziprasidone

Indexed keywords

ZIPRASIDONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG SAFETY; FEMALE; FUNCTIONAL ASSESSMENT; GRIP STRENGTH; LOCOMOTION; LOW DRUG DOSE; MOTOR ACTIVITY; MOTOR PERFORMANCE; MOUSE; NONHUMAN; PARKINSON DISEASE; REST; ROTAROD TEST; TREMOR;

EID: 84863955028     PISSN: 18117775     EISSN: 18125700     Source Type: Journal    
DOI: 10.3923/ijp.2012.396.402     Document Type: Article

References (35)

1. Amid, A, R.J.M. Salim and MI. Adenan, 2010. The factors affecting the extraction condition for neuroprotective activity of Centella asiatica evaluated by metal chelating activity assay. J. Applied Sci., 10: 837-842.
2. Ansari, JA., A. Siraj and N.N. Inamdar, 2010. Phmacotherapeutic approaches of Parkinsons disease. Int. J. Phmacol., 6: 584-590.
3. Ardestani, MS., 2010. Parkimon's dsease, ýnflammatory pathway and anti-inflammatory dmgs: An overview. J. Med. Sci., 10: 49-58.
4. Duggal, H.S. and I. Singh, 2008. Ziprasidone for dmg-induced psychotic symptoms in Parkinson's disease. Prog. Neuropsychophmacol. Biol. Psychiahy, 32: 583-584.
5. Dm-Ferreras, E., M. Alvarez-Lope and J.M. Garcia-Moreno and J. Chacon, 2008. Ziprasidone in parkimonian dopamine psychosis. Rev. Neurol, 46: 476-480.
6. Eng, M.L. and T.E. Welty, 2010. Management of hallucinations and psychosis in Parkinson's disease. Am. J. Geriatr. Phmacother., 8: 316-330.
7. Femandez, H.H., ME. Trieschmann and J.H. Friedman, 2003. Treatment of psychosis in Parkinson's disease: Safety comiderations. Drug. Saf., 26: 643-659.
8. Friedman, J.H., R.M. Beman, C.G. Goetz, S.A. Factor and W.G. Ondo et al., 2006 Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov. Disord., 21: 2078-2081
9. GadElhak, S.A., A.A.A. Ghanem, H. Abdelghaffar, S. El-Dakroury and M.M. Salama, 2010. Parkimon's disease: Is it a toxic syndrome? Neurol Res. Int., 2010: 1-10,
10. Gomez-Esteban, J.C., B. Tiero, J. Somme, R. Ciorda and K. Berganzo et al., 2011. Impact of psychiatric symptoms and sleep disorders on the quality of life of patients with Parkimon's dsease. J. Neurol, 258: 494-499.
11. Gomez-Esteban, J.C., J.J. Zarranz, F. Velasco, E. Lezcano, M.C. Lachen et al., 2005. Use of ziprasidone in parkinsonian patients with psychosis. Clin. Neurophannacol., 28: 111-114.
12. Keck, P. Jr., A. Buffenstein, J. Ferguson, J. Feighner, W. Jaffe, E.P. Hanigan and MR. Morrissey, 1998. Ziprasidone 40 and 120 mglday in the acute exacerbation of schzophrenia and schzoaffective disorder: A 4-week placebo-controlled trial. Psychophannacol., 140: 173.1 84.
13. Kummer, A. and A.L. Telxeira, 2009. Neuropsychiatry of Parkinson's dsease. Arq. Neuro-Psiquiatr., 67: 930-939.
14. Lerkundi, U., J. Peral, O. Mora, S. Domingo-Echabuu, M.J. Mdnez-Bengoechea and J.C. Garcia-Monco, 2008. Antidopaminergic therapy for managing comorbidities in patients with Parkimon's disease. Am. J. Health Syst. Phann., 65: 414-419.
15. Masri, B., A. Salahpour, M. Didriksen, V. Ghsi, J.M. Beaulieu, R.R. Gainetdinov and M.G. Caron, 2008. Antagonism of dopamine D2 receptorhetaarrestin 2 interaction is a common property of clinically effective antipsychotics Proc. Nat. Acad. Sci. USA., 105: 13656-13661
16. Meltzer, H.Y., 1991. The mechanism of action of novel antipsychotic dmgs. Schzophr. Bull., 17: 263-287.
17. Moran, P.M., L.S. Higgim, B. Cordell and PC. Moser, 1995. Age-related leaming deficits in transgenic mice expressing the 751-amino acid isoform ofhuman beta-myloid precursor protein. Roc. Natl. Acad. Sci. USA., 92: 5341-5345.
18. Oechsner, M. and A. Korchounov, 2005. Parenteral ziprasidone: A new atypical neuroleptic for emergency treatment of psychosis in Parkinson's diseases. Human Psychophannacol. Clin Exp., 20: 203-205.
19. Owiredu, W.K.B.A., J. Appiah-Poh, F. Adusei-Poh, N. Amidu and Y. Osei, 2009. The impact of blood glucose and cholesterol levels on the manifestation ofpsychatric dsorders. Pak. J. Biol Sci., 12: 252-257.
20. Pandy, V., N. Jose andH Subhash, 2009. CNS activity of methanol and acetone extracts of Acorus calamus leaves inmice. J. Phannacol. Toxicol., 4: 79-86.
21. Poewe, W. and K. Seppi, 2001. Treatment optiom for depression and psychosis in parkimon's disease. J. Neurol, 248: 3112-3121,
22. Rabey, JM., 2009. Hallucinations and psychosis in Parkimon's dsease. Parkinsonism Relat. Disord., 4: S105-S110.
23. Ravina, B., K. Marder, H.H. Femandez, J.H. Friedman and W. McDonald et al., 2007. Diagnostic criteria for psychosis in Parkimon's dsease: Repod of an NINDS, NIMH work group. Mov. Disord., 22: 1061-1068.
24. Sahin, I., M. Tuncer and M. Ilhan, 1990. Dopamine receptor agonists, N,N-dpropyl-2-aminotetralin (TL-68) and2-dapropylamino-4,7-dmethoxyindane (RDS-127) antagonize oxotremorine-induced tremors by antlmuscarinic action in mice. Arch. Int. Physiol. Biochlm., 98: 7-9.
25. Sameri, MJ., A. Sarkaki, Y. Farbood and S.M.T. Mamoui, 2011. Motor dsorders and ympaired electrical power of pallidal eeg ymproved by gallic acid in animal model of Parkinson's disease. Pak. J. Biol Sci., 14: 1109-1116.
26. Sarkaki, A, M. Badavi, H. Aligholi and A.Z. Moghaddam, 2009. Preventive effects of soy meal (+/- isoflavone) on spatial cognitive deficiency and body weight in an ovariectomized animal model of Parkinson's disease. Pak. J. Biol Sci., 12: 1338-1345.
27. Schndehutte, J. and C. Trenkwalder, 2007. Treatment of dmg-induced psychosis in Parkinson's dsease with ziprasidone can induce severe dose dependent off-periods and pathological laughing. Clin Neurol. Neurosurg., 109: 188-191
28. Schrag, A, 2004. Psychatric aspects of Parkinson's disease. J. Neurol, 251: 795-804.
29. Shelton, R.C. and GI. Papakostas, 2008. 'Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder. ActaPsychiatr. Scand, 117: 253-259.
30. Shiah, IS., C.L. Lin, W.C. Mao and S.U. Luu, 2006. Ziprasidone in the treatment of Parkimon's dsease psychosis. Eur. Psychatry., 21: 578-579.
31. Submanian, S., C. Rummel-Kluge, H. Hunger, F. Schmid and S. Schwarz et al., 2010. Zotepine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst. Rev., 101002114651858. CD006628pub3.
32. Tahr, N.M. and H.H. Manap, 2012. Parkimon disease gait classification based on machne learning approach. J. Applied Sci., 12: 180-185.
33. UmaDevi, P. and P Chkswamy, 2008. Age andgender related changes in free radcal pathology and antioxidant defeme in schizophrenia. Asian J. Blochem., 3: 143-152.
34. Weintraub, D. and HI. Hutig, 2007. Presentation and management of psychosis in Parkinson's dsease and dementia with lewy bodes. Am. J. PsychiaQ., 164: 1491-1498.
35. Zahodne, L.B. and H.H. Femandez, 2008. Pathophysiology and treatment of psychosis in Parkinson's dsease: A review. Drugs Aging., 25: 665-682.